Skip to main content

Table 1 Clinical activity and deepening of response of efficacy-evaluable population at 12.7 month median follow-up2 (N = 38)*

From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

Clinical response

Number of patients (%)

Confirmed ORR (CR + PR)

20 (53%)

Complete response (CR)

13 (34%)

DCR (CR + PR + SD**)

28 (74%)

ORR in PD-L1 negative (n = 14)

6 (43%)

ORR, PD-L1 positive (n = 21)

13 (62%)

ORR, PD-L1 unknown (n = 3)

1 (33%)

ORR, LDH > ULN (n = 11)

5 (45%)

ORR, liver metastases (n = 10)

5 (50%)

  1. *Data as of March 29, 2019 cut-off date. **Disease control rate, defined as complete response or partial response or stable disease for at least 8 weeks